Bone Destruction in Multiple Myeloma
- 1 April 2006
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1068 (1) , 319-326
- https://doi.org/10.1196/annals.1346.035
Abstract
Multiple myeloma (MM) is characterized by accumulation of monoclonal plasma cells in the bone marrow and progression of lytic bone lesions. MM cells enhance bone resorption by triggering a coordinated increase in RANK ligand and decrease in osteoprotegerin in the bone marrow. Macrophage inflammatory protein (MIP)-1alpha and (MIP)-1beta are secreted by MM cells, and play a major role in the enhancement of bone resorption by MM cells. Furthermore, the growth and survival of MM cells are enhanced by contact with osteoclasts (OCs) suggesting the presence of a vicious cycle between OCs and MM cells. OCs also enhance angiogenesis in concert with MM cells largely through the cooperative actions of osteopontin from OCs and VEGF from MM cells. The angiogenic effect may further facilitate the vicious cycle between bone destruction and MM cell expansion. In addition, MM cells secrete soluble factor(s) to suppress bone formation. Secreted Frizzled-related protein (sFRP)-2, an inhibitor of Wingless type (Wnt) binding to Frizzled, is produced by most MM cells, and immunodepletion of sFRP-2 abrogates the inhibition of bone formation. Thus, MM cells enhance bone resorption and suppress bone formation to cause destructive bone lesions. Further elucidation of the mechanism of bone destruction by MM may lead to a novel therapeutic approach to prevent bone destruction and tumor growth.Keywords
This publication has 11 references indexed in Scilit:
- Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansionBlood, 2004
- Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myelomaBritish Journal of Haematology, 2004
- The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple MyelomaNew England Journal of Medicine, 2003
- Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myelomaBlood, 2002
- High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5New England Journal of Medicine, 2002
- LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye DevelopmentCell, 2001
- Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myelomaBlood, 2000
- Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell LinesBlood, 1999
- Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.Journal of Clinical Oncology, 1998
- Multiple MyelomaNew England Journal of Medicine, 1997